
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Sideroblastic anemia epidemiology and demographics
Introduction
Overview
Overview
Patients of all age groups may develop sideroblastic anemia. The incidence of acquired sideroblastic anemia increases with age; the median age at diagnosis is 74 years. Chronic sideroblastic anemia is usually first diagnosed among middle and older age group. There is no racial predilection to sideroblastic anemia. Males are more commonly affected than females in X-linked recessive types of sideroblastic anemia.
Epidemiology and Demographics
Epidemiology and Demographics
Age
- Patients of all age groups may develop sideroblastic anemia.
- Congenital X-linked sideroblastic anemia due to ALAS mutation can remain undiagnosed and then present late in the fourth to eighth decades of life.
- The incidence of acquired sideroblastic anemia increases with age; the median age at diagnosis is 74 years.
- Chronic sideroblastic anemia is usually first diagnosed among middle and older age group.[1]
Race
- There is no racial predilection to sideroblastic anemia.
Gender
- Males are more commonly affected than females in X-linked recessive types of sideroblastic anemia.
- A female would have to inherit 1 abnormal chromosome from each parent to acquire the sideroblastic anemia.
- Primary acquired sideroblastic anemia was found in 60.4% male and 39.6% female.[1]
Region
- Sideroblastic anemia is more prevalent in European countries,in peadiatric population.
References
References
- ↑ 1.0 1.1 Hadnagy C (1991). “Primary acquired sideroblastic anemia and myelodysplastic syndrome from a geriatric point of view”. Z Gerontol. 24 (2): 105–9. PMID 1877285.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nazia Fuad M.D.
